Nature Communications (Aug 2017)
ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways
- Thuc M. Le,
- Soumya Poddar,
- Joseph R. Capri,
- Evan R. Abt,
- Woosuk Kim,
- Liu Wei,
- Nhu T. Uong,
- Chloe M. Cheng,
- Daniel Braas,
- Mina Nikanjam,
- Peter Rix,
- Daria Merkurjev,
- Jesse Zaretsky,
- Harley I. Kornblum,
- Antoni Ribas,
- Harvey R. Herschman,
- Julian Whitelegge,
- Kym F. Faull,
- Timothy R. Donahue,
- Johannes Czernin,
- Caius G. Radu
Affiliations
- Thuc M. Le
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Soumya Poddar
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Joseph R. Capri
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Evan R. Abt
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Woosuk Kim
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Liu Wei
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Nhu T. Uong
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Chloe M. Cheng
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Daniel Braas
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Mina Nikanjam
- Division of Hematology-Oncology, University of California, Los Angeles
- Peter Rix
- Vector Pharma Advisors Inc.
- Daria Merkurjev
- Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles
- Jesse Zaretsky
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Harley I. Kornblum
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Antoni Ribas
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Harvey R. Herschman
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Julian Whitelegge
- The Pasarow Mass Spectrometry Laboratory, Neuropsychiatric Institute-Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles
- Kym F. Faull
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Timothy R. Donahue
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Johannes Czernin
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- Caius G. Radu
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles
- DOI
- https://doi.org/10.1038/s41467-017-00221-3
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 14
Abstract
Leukemic cells depend on the nucleotide synthesis pathway to proliferate. Here the authors use metabolomics and proteomics to show that inhibition of ATR reduced the activity of these pathways thus providing a valuable therapeutic target in leukemia.
